The drug is approved for multiple inflammatory conditions and is expected to launch in the first half of 2025.
At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...
Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.
US FDA approves UCB’s 320 mg single-injection device presentations of Bimzelx: Brussels, Belgium Tuesday, October 15, 2024, 13:00 Hrs [IST] UCB, a global biopharmaceutical compa ...
“This FDA approval indicates global ... a blockbuster drug developed by Janssen Biotech for the treatment of patients with ...
Individuals with self-reported moderate to severe psoriatic arthritis (PsA) face a higher disease burden, particularly among ...
PRNewswire Ahmedabad Gujarat [India] October 14 Accord BioPharma Inc the US specialty division of Intas Pharmaceuticals Ltd ...
Dong-A ST's biosimilar product Imuldosa has been approved by the U.S. Food and Drug Administration (FDA), the Korean ...
Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.
Imuldosa (ustekinumab-srlf) is the fifth ustekinumab biosimilar referencing Stelara to receive regulatory approval in the US.
“The heroes here tonight are not make-believe heroes from Marvel Comics, but real-life heroes who have made an impact on ...
Imuldosa is the latest FDA-approved biosimilar of J&J’s blockbuster therapy for the treatment of certain autoimmune diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback